X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs IPCA LABS - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH IPCA LABS PANACEA BIOTECH/
IPCA LABS
 
P/E (TTM) x -6.4 29.2 - View Chart
P/BV x 1.9 3.7 51.0% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 PANACEA BIOTECH   IPCA LABS
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
IPCA LABS
Mar-18
PANACEA BIOTECH/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs149695 21.4%   
Low Rs82400 20.6%   
Sales per share (Unadj.) Rs84.1260.2 32.3%  
Earnings per share (Unadj.) Rs-18.319.0 -96.5%  
Cash flow per share (Unadj.) Rs-6.733.1 -20.3%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs83.7213.0 39.3%  
Shares outstanding (eoy) m61.25126.20 48.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.42.1 65.2%   
Avg P/E ratio x-6.328.9 -21.9%  
P/CF ratio (eoy) x-17.216.6 -104.1%  
Price / Book Value ratio x1.42.6 53.7%  
Dividend payout %05.3 0.0%   
Avg Mkt Cap Rs m7,07469,120 10.2%   
No. of employees `0002.813.3 20.7%   
Total wages/salary Rs m1,4497,359 19.7%   
Avg. sales/employee Rs Th1,874.12,477.4 75.6%   
Avg. wages/employee Rs Th527.0555.2 94.9%   
Avg. net profit/employee Rs Th-407.7180.6 -225.7%   
INCOME DATA
Net Sales Rs m5,15432,836 15.7%  
Other income Rs m100418 23.9%   
Total revenues Rs m5,25433,254 15.8%   
Gross profit Rs m-7664,505 -17.0%  
Depreciation Rs m7111,777 40.0%   
Interest Rs m1,503240 625.7%   
Profit before tax Rs m-2,8812,905 -99.1%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m17511 3.3%   
Profit after tax Rs m-1,1212,394 -46.8%  
Gross profit margin %-14.913.7 -108.4%  
Effective tax rate %-0.617.6 -3.3%   
Net profit margin %-21.87.3 -298.4%  
BALANCE SHEET DATA
Current assets Rs m3,81019,455 19.6%   
Current liabilities Rs m8,36510,076 83.0%   
Net working cap to sales %-88.428.6 -309.4%  
Current ratio x0.51.9 23.6%  
Inventory Days Days15698 159.0%  
Debtors Days Days6767 100.4%  
Net fixed assets Rs m14,48020,260 71.5%   
Share capital Rs m61252 24.3%   
"Free" reserves Rs m90326,633 3.4%   
Net worth Rs m5,12726,886 19.1%   
Long term debt Rs m5,8322,340 249.2%   
Total assets Rs m19,43341,173 47.2%  
Interest coverage x-0.913.1 -7.0%   
Debt to equity ratio x1.10.1 1,306.8%  
Sales to assets ratio x0.30.8 33.3%   
Return on assets %2.06.4 30.7%  
Return on equity %-21.98.9 -245.6%  
Return on capital %3.610.8 33.8%  
Exports to sales %24.547.6 51.5%   
Imports to sales %10.214.9 68.5%   
Exports (fob) Rs m1,26415,642 8.1%   
Imports (cif) Rs m5254,884 10.7%   
Fx inflow Rs m1,53915,642 9.8%   
Fx outflow Rs m9424,884 19.3%   
Net fx Rs m59710,759 5.6%   
CASH FLOW
From Operations Rs m5993,411 17.6%  
From Investments Rs m-438-1,354 32.3%  
From Financial Activity Rs m-303-1,304 23.2%  
Net Cashflow Rs m-141753 -18.8%  

Share Holding

Indian Promoters % 74.5 45.9 162.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 11.4 5.3%  
FIIs % 1.3 25.3 5.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 17.4 135.6%  
Shareholders   10,259 36,892 27.8%  
Pledged promoter(s) holding % 35.1 2.1 1,638.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   UNICHEM LAB  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  SUN PHARMA  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Dec 14, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS